← Azimuth Daily
Capturing data…
Capturing data…
THU, 12 NOV · 87 ITEMS
"Deaths during gene-editing therapy trials in China reveal governance gaps" — Nature Medicine · Science & Medicine
This is a commentary piece in Nature Medicine analyzing deaths that occurred during trials in China, specifically highlighting gaps in governance and oversight. The article likely discusses two known fatal cases: a 6-year-old girl who died in March 2025 from a severe immune reaction after receiving , and a child enrolled in a HuidaGene trial for who also died. The piece examines how China's regulatory framework, including the investigator-initiated trials (IIT) pathway, failed to ensure timely disclosure and adequate safety monitoring.
The claim is highly solid as it comes from a primary source—a Nature Medicine article (doi:10.1038/s41591-026-04768-x) that is itself a peer-reviewed commentary or analysis. The reporting sits close to the underlying events, which have been independently reported by Science, STAT News, and other outlets, confirming two deaths in separate gene-editing trials in China during 2025-2026. The Nature Medicine piece is authoritative about its own analysis, though the specific governance gaps it identifies are editorial interpretations.
Genuinely new: the Nature Medicine article was published in 2026, and the deaths it discusses occurred in 2025-2026, making this a current analysis of recent events.
We covered the fatal gene-editing trial in China in July 2026, raising ethics and oversight questions, and again in September 2026 when the deaths put a spotlight on trials in China.